Status:
COMPLETED
Post Marketing Survey of Vesicare in Japan
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Overactive Bladder
Eligibility:
FEMALE
Brief Summary
This study is to evaluate the effect of Vesicare on quality of life (QOL) in female patients.
Detailed Description
Overactive bladder (OAB) represents a constellation of symptoms that must include urinary urgency as an essential symptom for the diagnosis. It is usually accompanied by daytime frequency and nighttim...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Previously untreated OAB patients
- Patients who meet the diagnostic criteria for OAB provided in the clinical guidelines for overactive bladder (patients who have urinary urgency at least once weekly as an essential symptom and at least one of the other OAB symptoms including daytime frequency, nighttime frequency, and urgency incontinence)
- Patients who can understand and answer OAB-q (Japanese version)
- Patients from whom data on all items concerning OABSS, OAB-q, and satisfaction score for urination can be obtained at baseline
- Patients who are expected to be treated for at least 12 weeks
Exclusion
Key Trial Info
Start Date :
June 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
1160 Patients enrolled
Trial Details
Trial ID
NCT01489709
Start Date
June 1 2010
End Date
April 1 2011
Last Update
September 5 2014
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Chugoku, Japan
2
Chūbu, Japan
3
Hokkaido, Japan
4
Kansai, Japan